Tag Archives: Ram Selvaraju

H.C. Wainwright Believes Eton Pharmaceuticals (NASDAQ: ETON) Won’t Stop Here

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eton Pharmaceuticals (ETON – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $8.28, close to its 52-week high

H.C. Wainwright Thinks Kitov Pharmceuticals’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kitov Pharmceuticals (KTOV – Research Report) today and set a price target of $25.00. The company’s shares closed last Friday at $4.06, close to its 52-week low of $2.20. According

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Chemed (NYSE: CHE) and Blueprint Medicines (NASDAQ: BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Chemed (CHE – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments. Genmab (GMAB)

H.C. Wainwright Reiterates a Buy Rating on Kezar Life Sciences (KZR)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences (KZR – Research Report) today and set a price target of $12.00. The company’s shares closed last Monday at $4.98. According to TipRanks.com, Selvaraju is a 5-star

H.C. Wainwright Thinks Oncternal Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $2.17, close to its 52-week low of $1.96. According

Tiziana Life Sciences (TLSA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Tiziana Life Sciences (TLSA – Research Report) today and set a price target of $11.00. The company’s shares closed last Friday at $3.93. According to TipRanks.com, Selvaraju is a 5-star